As I noted earlier and in an updated piece, I am, on balance, encouraged by today's update from Skinbiotherapeutics (SBTX).Not enough to buy as I still have cash concerns but I am not selling and I can see potentially huge upside. But judge for yourself. Here is the presentation by the biggest drag on the share price, Stuart Ashman. Enjoy.
I cannot really fault the trading update from Skinbiotherapeutics (SBTX) today covering the year to June 30 2024in terms of the detail given. The only worry is the low cash position but there are plenty of positives. The note from house broker Cavendish is entirely reasonable and, with a following wind, its 48p price target might be very lame indeed. But…
This is good news from Skinbiotherapeutics (SBTX): there will be no more death spiral selling as the last £480,000 of the facility arrange by fraud enabler Charles Ofori has been converted into shares placed with one existing and several new investors. But…
It was not that long ago that the bearded poltroon Stuart Ashman said he was going to replace the death spiral facility he had negotiated with disgraced prospectus fraud enabler Charles Ofori and now managed by Macquarie. Of course, that did not happen.
I am told by those who understand Skinbiotherapeutics (SBTX) far better than I do that it is not if Croda starts placing orders as part of its jv but the scale of those orders and the pricing. Not having the intelligence of a lemming I am prepared to accept that and as a loyal shareholder very much hope that it is true. However, good news travels fast, bad news is oft delayed.
Another day and another reason why the bearded Geordie poltroon Stuart Ashman should be sacked as CEO of Skinbiotherapeutics (SBTX), where I remain a loyal shareholder.
I was aware of no reason for shares in Skinbiotherapeutics (SBTX) spiked to 13.5p last week. I assumed it was some sort of dump ahead of a you know what. Well, with the shares coming all the way back, the rumour is that bearded loon Stuart Ashman is trying to do a placing: 10p vicar? The aim?
Why on earth are shares in Skinbiotherapeutics (SBTX) up by 32% at 11.25p today I am asked. Do not get me wrong, I am not complaining. My breakeven on this one is c16p and I’d be over the moon if all comes good and I can start deciding which goats to buy as I explained HERE. But….
From Skinbiotherapeutics (SBTX) today comes news of a management change. Sadly it is not one of the three that I had been hoping for.
At least Stuart Ashman of Skinbiotherapeutics (SBTX) has now admitted that the death spiral taken out with CLG Capital is a very bad financing option as some of us pointed out right from the start, and were told we did not know what we were talking about!. He says that he will not draw down any more on the facility but, after two conversions, there are still £1.47 million of loan notes outstanding.







